Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell Lymphoma

NCT07285590 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Mantle Cell Lymphoma (MCL)

Interventions

DRUG: Pirtobrutinib and rituximab

Sponsor

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Collaborators

Evidenze CRO
Eli Lilly and Company